vilastobart
vilastobart: sourced relationships with 1 company · 2 clinical trials tracked.
vilastobart evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could vilastobart → XLO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Xilio Therapeutics, Inc. (XLO) | Phase 1/Phase 2 |
Clinical Trial Registry Records (2)
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Primary endpoint: Objective response rate (ORR)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients With Advanced Solid Tumors
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) in Part 1A
Frequently asked questions
Which companies have sourced relationships with vilastobart?
vilastobart has dated SEC/FDA relationship records for Xilio Therapeutics, Inc..
How many clinical trials involve vilastobart?
BioSniper tracks 2 clinical trials involving vilastobart.